✦ LIBER ✦

Mitoxantrone in the treatment of advanced non-squamous carcinoma of the cervix (A phase II trial of the gynecologic oncology group)

✍ Scribed by Hyman B. Muss; Brian N. Bundy; Howard D. Homesley; George Wilbanks

Publisher: Springer US
Year: 1987
Tongue: English
Weight: 247 KB
Volume: 5
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00203546

No coin nor oath required. For personal study only.

✦ Synopsis

Twenty-five evaluable patients with advanced non-squamous carcinoma of the uterine cervix were treated with mitoxantrone 12 mg/m 2 every three weeks. All patients had good performance status and measurable disease and'only 11 had received prior chemotherapy. One complete and one partial response were noted among 15 patients with no prior chemotherapy while no responses were seen in 11 previously treated patients. The major toxicity was myelosuppression; other toxicity was mild. The median progression-free interval was 2.1 months and median survival 4.3 months. Mitoxantrone displays minimal activity in patients with advanced non-squamous carcinoma of the cervix.

📜 SIMILAR VOLUMES

A phase II trial of pyrazoloacridine (PZ

A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

✍ Steven C. Plaxe; John A. Blessing; George Olt; Nader Husseinzadah; Samuel S. Len 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 71 KB

Cis-platinum in treatment of advanced or

Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: A phase ii study of the gynecologic oncology group

✍ Tate Thigpen; Hugh Shingleton; Howard Homesley; Leo Lagasse; John Blessing 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 482 KB 👁 3 views

Phase II evaluation of mitoxantrone in a

Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group study

✍ Sarah A. Taylor; Thomas Fleming; Daniel D. Hoff; Joseph D. McCracken; Ronald M. 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 242 KB

Patient with advanced adenocarcinoma of the pancreas and no prior chemotherapy were treated on a Phase II trial of mitoxantrone. Doses were adjusted for hepatic dysfunction as defined by bilirubin. Twenty-four patients with a bilirubin less than or equal to 1.5 mg% received mitoxantrone 12 mg/m2 i.v

An eastern cooperative oncology group ph

An eastern cooperative oncology group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma

✍ Robert S. Witte; Paul Elson; Janardan Khandakar; Donald L. Trump 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 359 KB 👁 2 views

## Background. Trimetrexate is an antifol that differs from methotrexate in ways that may be clinically important. Because methotrexate has activity in advanced bladder cancer, this trial was initiated.

Phase II evaluation of dianhydrogalactit

Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma

✍ Frederick B. Stehman; John A. Blessing; Howard D. Homesley; John L. Currie; Edga 📂 Article 📅 1984 🏛 Springer US 🌐 English ⚖ 139 KB

In an on-going Phase II evaluation, dianhydrogalactitol (NSC 132313) was administered intravenously to 28 patients with advanced or recurrent non-squamous cell carcinoma of the cervix. The initial dosage was 60 mg/m 2/wk with escalation to 75 mg/m z/wk if there were no adverse effects. Twenty-seven

Phase II study of esorubicin (4′-deozydo

Phase II study of esorubicin (4′-deozydoxorubicin) in advanced epithelial carcinoma of the ovary:A Gynecologic Oncology Group study

✍ William P. McGuire; John A. Blessing; Michael L. Berman 📂 Article 📅 1989 🏛 Springer US 🌐 English ⚖ 275 KB

Twenty-six patients with advanced, measurable epithelial carcinoma of the ovary were treated with 76 courses of esorubicin at doses ranging from 20-30 mg/m2 every 3 weeks. All patients are evaluable for toxicity and response. All patients had received prior therapy including radiation therapy in 9,